William Blair Brokers Raise Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at William Blair increased their Q2 2026 EPS estimates for Harrow in a research note issued to investors on Tuesday, November 11th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of $0.49 for the quarter, up from their previous forecast of $0.47. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow’s Q4 2026 earnings at $0.83 EPS.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.11. The business had revenue of $71.64 million during the quarter, compared to analysts’ expectations of $73.70 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.

A number of other analysts also recently issued reports on HROW. BTIG Research reissued a “buy” rating and issued a $63.00 price objective on shares of Harrow in a report on Wednesday, September 24th. LADENBURG THALM/SH SH lifted their price target on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday. B. Riley reissued a “buy” rating and set a $74.00 price target (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Cantor Fitzgerald restated an “overweight” rating and set a $94.00 price objective on shares of Harrow in a research note on Tuesday. Finally, Craig Hallum lifted their price objective on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Harrow has a consensus rating of “Moderate Buy” and a consensus price target of $71.43.

Harrow Stock Performance

HROW stock traded up $1.17 during trading hours on Thursday, hitting $39.61. 290,357 shares of the stock were exchanged, compared to its average volume of 551,711. The company has a 50-day simple moving average of $40.69 and a two-hundred day simple moving average of $34.87. The firm has a market capitalization of $1.47 billion, a P/E ratio of -157.70 and a beta of 0.19. Harrow has a 12 month low of $20.85 and a 12 month high of $50.72. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78.

Hedge Funds Weigh In On Harrow

Hedge funds have recently bought and sold shares of the company. Hussman Strategic Advisors Inc. acquired a new position in shares of Harrow during the 1st quarter valued at $559,000. Royce & Associates LP lifted its stake in Harrow by 12.0% during the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock valued at $8,701,000 after acquiring an additional 35,006 shares in the last quarter. Equitable Trust Co. grew its position in Harrow by 9.2% in the 1st quarter. Equitable Trust Co. now owns 47,570 shares of the company’s stock worth $1,265,000 after purchasing an additional 4,015 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Harrow during the first quarter valued at approximately $2,046,000. Finally, HighTower Advisors LLC boosted its holdings in shares of Harrow by 30.5% in the 1st quarter. HighTower Advisors LLC now owns 13,217 shares of the company’s stock worth $352,000 after buying an additional 3,090 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.